NN703: Research, Dosing, and Where to Buy in 2026
A research-first profile for NN703, aggregating mechanism notes, transcript dosing mentions, vendor recommendations, and PubMed-indexed literature without presenting medical guidance.
NN703 is a research compound profiled here from named-expert transcripts and peer-reviewed literature, without medical guidance. As of July 2026, The Peptide Wiki aggregates 8 PubMed-cited papers for NN703, each linked to its source.
- 0 aggregated dosing-protocol mentions from source transcripts.
- 8 PubMed-indexed citations listed in the research table below.
- 0 vendor recommendations captured from named experts.
What is NN703?
Research compound aggregated from creator and literature mentions. No direct disease-treatment claims are made on this page.
NN703 Dosing Protocols
The entries below are transcript-derived dosing mentions. They are preserved for research context and are not medical advice.
No transcript-derived dosing mentions in current source set.
Where to Buy NN703 in 2026
No tracked vendor recommendations for NN703 yet. See our vendor directory.
Side Effects and Safety
Anecdotal reports and study-level observations vary by route, dose, and individual. This page does not provide medical advice. Consult a qualified clinician before any research use.
User Reviews
User reviews aggregator coming Q3 2026 (Reddit + YouTube comments + Discord research notes). Until then, see the expert quote section above and PubMed citations below.
Research Efficacy Snapshot
Published efficacy percentages cited in PubMed trials and named-expert reports about NN703. Each line links to the original source.
- "Nine of the 83 patients (11%) responded with a serum peak GH concentration >or= 5 micro g/l after the first and/or last NN703 administration, whereas no patient responded after placebo administration." · Svensson J et al, 2003 PubMed
- "Following a single dose of NN703 (day 3), the AUC of both midazolam and alpha-hydroxymidazolam increased by 64% and 34%, respectively (P=0.0001 for both)." · Zdravkovic M et al, 2003 PubMed
- "After repeated NN703 dosing (day 9), NN703 levels reached steady state, and midazolam AUC further increased to 93% relative to baseline (P=0.0001), whereas alpha-hydroxymidazolam AUC decreased slightly and was 11% higher than baseline (n.s.)." · Zdravkovic M et al, 2003 PubMed
- "Following the washout period (day 16), midazolam AUC decreased to values lower than those on day 3 and day 9, but still significantly (45%) higher than baseline levels (P=0.0001)." · Zdravkovic M et al, 2003 PubMed
- "The four compounds showed oral bioavailability around 35% and equipotency in vitro compared to NN703." · Ankersen M et al, 2000 PubMed
- "A 50% increase of cortisol, compared with basal levels, was observed for all the tested doses of NN703, but no dose-dependency was shown." · Hansen B et al, 1999 PubMed
- "The oral bioavailability was 30%." · Hansen B et al, 1999 PubMed
Research and Studies
8 PubMed-indexed papers reference NN703. Top 8 shown.
Legal Status
NN703 is presented here as a research compound. FDA approval status, scheduling, WADA status, and state-specific telehealth rules may apply. Always verify current regulatory status. Last verified: 2026-07-09.
Frequently Asked Questions
Is NN703 FDA-approved?
NN703 is presented on this page as a research compound. FDA approval status, scheduling, and state-specific rules may apply and change. Verify current regulatory status before any decision.
How much research has been published on NN703?
8 PubMed-indexed paper(s) reference NN703 in our current research feed. See the Research and Studies section above for citations.